(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 December 2022 (29.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/269531 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *C07D 519/00* (2006.01)
C07D 471/04 (2006.01) *A61K 31/519* (2006.01)

(21) International Application Number:
PCT/IB2022/055827

(22) International Filing Date:
23 June 2022 (23.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/215,435	26 June 2021 (26.06.2021)	US
63/294,590	29 December 2021 (29.12.2021)	US
63/350,495	09 June 2022 (09.06.2022)	US

(71) Applicant: **ARRAY BIOPHARMA INC.** [US/US]; 3200 Walnut Street, Boulder, Colorado 80301 (US).

(72) Inventors: **ELLIS, Bryan Daniel**; 2736 Yates St., Denver, Colorado 80212 (US). **HICKEN, Erik James**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **LAIRD, Ellen Ruth**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **LAZZARA, Nicholas Charles**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **NEWHOUSE, Bradley Jon**; 226 Berthoud Trail, Broomfield, Colorado 80020 (US). **PAJK, Spencer Phillip**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **ROSEN, Rachel Zoe**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **SHELP, Russell Andrew**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route 206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New Jersey 07977 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: HER2 MUTATION INHIBITORS



(I)

(57) Abstract: This invention relates to compounds of Formula (I): (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L^2, R^1, R^2, R^3, R^4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

WO 2022/269531 A1